Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Kammlott

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Biochemistry|June 12, 1998
Protein farnesyltransferase: structure and implications for substrate bindingP Dunten, U Kammlott, R Crowther, et al.
Protein Science : a Publication of the Protein Society|April 24, 2001
X-ray structure of a novel matrix metalloproteinase inhibitor complexed to stromelysinP Dunten, U Kammlott, R Crowther, et al.
Protein Engineering|July 6, 2000
Expression, characterization and structure determination of an active site mutant (Glu202-Gln) of mini-stromelysin-1D L Steele, O El-Kabbani, P Dunten, et al.
Journal of Medicinal Chemistry|June 8, 2000
Peptide and peptide mimetic inhibitors of antigen presentation by HLA-DR class II MHC molecules. Design, structure-activity relationships, and X-ray crystal structuresD R Bolin, A L Swain, R Sarabu, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Biochemistry|June 12, 1998
Protein farnesyltransferase: structure and implications for substrate bindingP Dunten, U Kammlott, R Crowther, et al.
Protein Science : a Publication of the Protein Society|April 24, 2001
X-ray structure of a novel matrix metalloproteinase inhibitor complexed to stromelysinP Dunten, U Kammlott, R Crowther, et al.
Protein Engineering|July 6, 2000
Expression, characterization and structure determination of an active site mutant (Glu202-Gln) of mini-stromelysin-1D L Steele, O El-Kabbani, P Dunten, et al.
Journal of Medicinal Chemistry|June 8, 2000
Peptide and peptide mimetic inhibitors of antigen presentation by HLA-DR class II MHC molecules. Design, structure-activity relationships, and X-ray crystal structuresD R Bolin, A L Swain, R Sarabu, et al.
Pageof 1